In this issue:
Smartwatch-enabled detection of LV dysfunction
Dapagliflozin in patients with HF with improved ejection fraction
Empagliflozin in HF patients with preserved vs mid-range ejection fraction
Trends and real-world safety of PCI for stable ischaemic heart disease
Low-dose rosuvastatin vs dietary supplements
Reanalysis of mortality data from the FOURIER trial
Effects of olpasiran on lipoprotein(a) levels in patients with ASCVD
Screening for risk of sudden cardiac death in young competitive athletes
Baxdrostat for treatment-resistant hypertension
Major cardiovascular events and subsequent risk of kidney failure requiring replacement therapy
Please login below to download this issue (PDF)